Turbine Simulated Cell Technologies, founded in 2015 in Budapest, Hungary, develops an AI-based platform for simulating cancer cell biology.
Founded in 2015 by Dániel Veres, Kristóf Zsolt Szalay and Szabolcs Nagy, and based in Budapest, Hungary, Turbine Simulated Cell Technologies Ltd. develops a predictive simulation platform that uses computational models and machine learning to simulate tumor cell behavior. The platform helps predict drug-like effects and identify therapeutic targets. In February 2026 the company raised USD 25 million in Series B funding led by Interactive Venture Partners, with Beiersdorf AG, Accel, Mercia Asset Management, Merck Global and Health Innovation Fund participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in